BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
|
By LabMedica International staff writers Posted on 07 Aug 2019 |

Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
BioMérieux (Marcy-l'Étoile, France) showcased its unique and comprehensive range of diagnostic solutions that support the responsible use of antibiotics to improve patient care at AACC 2019. Among its diagnostic solutions highlighted at the tradeshow was Bact/Alert Virtuo, which along with bioMérieux’s Bact/Alert Virtuo blood culture system and Bact/Alert Fan Plus media, provides fast and actionable results for better antimicrobial stewardship.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more





.jpg)


